- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | Medicenna stock price target maintained at $2.50 by H.C. Wainwright | 2 | Investing.com | ||
| 26.06. | Medicenna Therapeutics Corp. GAAP EPS of -C$0.22 | 1 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | 213 | GlobeNewswire (Europe) | MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer... ► Artikel lesen | |
| 11.06. | Medicenna Therapeutics Corp: Medicenna receives two U.S. patents | 1 | Stockwatch | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.06. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp: Medicenna files prospectus for $5-million offering | 1 | Stockwatch | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | 3 | GlobeNewswire (USA) | ||
| 19.05. | Medicenna Therapeutics Corp: Medicenna sets out terms of public offering | 1 | Stockwatch | ||
| 19.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 19.05. | Medicenna prices public offering at $0.50 per unit | 5 | Investing.com | ||
| 13.05. | Medicenna launches public offering to fund clinical programs | 2 | Investing.com | ||
| 13.05. | Medicenna launches marketed public offering of securities | 1 | Seeking Alpha | ||
| 13.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Launch of a Marketed Public Offering of Securities | 1 | GlobeNewswire (USA) | ||
| 12.05. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 12.05. | Medicenna Therapeutics Corp.: Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | 192 | GlobeNewswire (Europe) | NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase... ► Artikel lesen | |
| 21.04. | Medicenna Therapeutics Corp: Medicenna releases MDNA113 preclinical data | 1 | Stockwatch | ||
| 21.04. | Medicenna Therapeutics Corp.: Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 370,68 | 0,00 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| RELAY THERAPEUTICS | 19,990 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,710 | +0,03 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 16,590 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| CG ONCOLOGY | 77,04 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| VERA THERAPEUTICS | 30,320 | +0,10 % | Vera Therapeutics GAAP EPS of -$1.52 beats by $0.04 | ||
| APOGEE THERAPEUTICS | 134,71 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,110 | -0,03 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| TANGO THERAPEUTICS | 26,320 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| ERASCA | 18,310 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 58,76 | -0,03 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 | ||
| PYXIS ONCOLOGY | 2,810 | -0,71 % | Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones | Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 5,100 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,800 | +0,17 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| SEPTERNA | 47,780 | 0,00 % | Septerna, Inc.: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results | Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.